Blog
RSS FeedPosted by Michael Wonder on 19 Feb 2018
Medication for rare soft-bone disease to be covered by public drug plans in Canada
15 February 2018 - One of the most expensive medications in the world is about to be covered by public ...
Posted by Michael Wonder on 16 Feb 2018
Quebec and New Brunswick become first provinces to provide public funding of Ibrance for the first-line treatment of metastatic breast cancer
15 February 2018 - Since Ibrance received Health Canada marketing authorisation in March 2016, Canadian women living with metastatic breast cancer ...
Posted by Michael Wonder on 15 Feb 2018
Canadian patient groups call on Federal Health Minister to halt the process examining proposed amendments to the Patented Medicine Regulations pending constructive consultations
15 February 2018 - Patient feedback has not been considered – groups seek meaningful dialogue with Government and drug manufactures ...
Posted by Michael Wonder on 15 Feb 2018
Canadians are being fooled into thinking we'll like pharmacare. We really, really won't.
15 February 2018 - The idea that a government-run drug insurance monopoly will cost less and deliver the same benefits as ...
Posted by Michael Wonder on 13 Feb 2018
Almost 1 million Canadians give up food, heat to afford prescriptions: study
13 February 2018 - 968,000 people skimped on necessities to pay for their medicine in 2016, researchers find. ...
Posted by Michael Wonder on 07 Feb 2018
Canadian generic drug prices higher than international levels in recent years
6 February 2018 - The Patented Medicine Prices Review Board releases its latest report on generic drug pricing in Canada. ...
Posted by Michael Wonder on 07 Feb 2018
AbbVie receives a positive recommendation from the CADTH Canadian Drug Expert Committee for Maviret – an oral therapy for the treatment of patients with hepatitis C
6 February 2018 - Maviret previously received a Notice of Compliance from Health Canada on 16 August 2017. ...
Posted by Michael Wonder on 06 Feb 2018
Quebec adds Erelzi (etanercept) to provincial drug plans for the treatment of multiple inflammatory diseases
5 February 2018 - Erelzi has been added to the Quebec Drug Insurance Plan based on specific criteria for the treatment ...
Posted by Michael Wonder on 05 Feb 2018
Acerus Pharma’s Natesto to be listed for public reimbursement in Quebec
1 February 2018 - Acerus Pharmaceuticals Corporation today announced that it has received notice from Quebec’s National Institute for Excellence ...
Posted by Michael Wonder on 04 Feb 2018
The real story behind the sudden drop in Canada's drug prices
3 February 2018 - And is Ontario offering a college diploma in 'pseudoscience?' ...
Posted by Michael Wonder on 30 Jan 2018
To avoid open bidding, generic-drug makers cut prices outside Quebec
30 January 2018 - The provinces outside Quebec are expecting to save as much as $3-billion over five years after ...
Posted by Michael Wonder on 29 Jan 2018
A joint statement from the pan-Canadian Pharmaceutical Alliance and the Canadian Generic Pharmaceutical Association
29 January 2018 - On behalf of participating federal, provincial, and territorial public drug plans, the pan-Canadian Pharmaceutical Alliance (pCPA), with ...
Posted by Michael Wonder on 21 Jan 2018
At $262.40 per pill, the cancer drug that could save her life isn’t covered in B.C.
19 January 2018 - Karen McLaren of Langley has stage four breast cancer, and has been prescribed a drug that could ...
Posted by Michael Wonder on 16 Jan 2018
How Ottawa's using a fake drug crisis to force through damaging pharmaceutical policy
16 January 2018 - There is no affordability crisis to justify expanding drug price regulation, or a new national government-run pharmacare ...
Posted by Michael Wonder on 15 Jan 2018
Parents of kids with rare neuromuscular disorder want funding for expensive drug
15 January 2018 - Parents whose children are battling a genetic disease called spinal muscular atrophy are calling on the ...